Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in Prophylaxis and Treatment of Acute and Chronic GVHD: Expert Guidance and Practical Considerations
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: July 29, 2021 Expiration: July 28, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation
Amin Alousi, MD
Sally Arai, MD
Corey S. Cutler, MD, MPH, FRCPC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review recent advances in our understanding of the underlying pathophysiology of GVHD and ongoing efforts to identify novel biomarkers and prognostic indicators to optimize clinical outcomes
  • Appraise the current and emerging prophylactic strategies for the prevention of GVHD and the latest evidence on innovative therapies for management of acute or chronic, steroid-refractory GVHD
  • Apply the most optimal evidence-based strategies for acute and chronic, previously untreated, and steroid-refractory GVHD based on individual patient and disease characteristics
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GVHD

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Amin Alousi, MD

Professor
Division of Cancer Medicine
Department of Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amin Alousi, MD, has disclosed that he has received consulting fees from Alexion, Kadmon, Medexus, and Prolacta, fees for non-CME services from Therakos, and funding for research from Incyte.
Sally Arai, MD

Associate Professor of Medicine
Blood and Marrow Transplantation and Cellular Therapy
Stanford University Medical Center
Stanford, California

Sally Arai, MD, MS, has no relevant conflicts of interest to report.
Corey S. Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey S. Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from CareDx, Fresenius-Kabi, Incyte, Janssen, Jazz, Kadmon, and Mesoblast, and other financial/material support from Omeros.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for transplant specialists, hematologist-oncologists, and other clinicians involved in the management of patients with GVHD.

Goal

The goal of this activity is to improve the knowledge and competence of clinicians in treating patients with hematologic malignancies with or at risk of GVHD.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 29, 2021, through July 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Diagnosis and Prophylaxis of GVHD
  • CME
  • MOC

Loading...
Get up to date on the latest multidisciplinary strategies to improve prophylaxis and treatment outcomes in patients with acute and chronic GVHD.
Amin Alousi, MD
Sally Arai, MD
Corey S. Cutler, MD, MPH, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: July 29, 2021 Expiration: July 28, 2022

This program is divided into several short segments that you can step through using the Video Chapters menu.
PreviousNext

Related Content

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue